Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug;83(2):237-279.
doi: 10.1016/j.jinf.2021.05.018. Epub 2021 May 25.

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

Beena Philomina J  1 , Bani Jolly  2 , Neethu John  3 , Rahul C Bhoyar  4 , Nisha Majeed  5 , Vigneshwar Senthivel  2 , Fairoz Cp  1 , Mercy Rophina  2 , Bindhu Vasudevan  6 , Mohamed Imran  2 , Prasanth Viswanathan  7 , V R Arvinden  2 , Anoop Joseph  8 , Mohit Kumar Divakar  2 , Priyanka R Nair  7 , Afra Shamnath  4 , P Jayesh Kumar  9 , Abhinav Jain  2 , P Geetha  9 , Anjali Bajaj  2 , Samatha Mathew  2 , Vishu Gupta  2 , Srashti Jyoti Agrawal  2 , Vinod Scaria  10 , Sridhar Sivasubbu  11 , Chandni Radhakrishnan  12
Affiliations
Comment

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

Beena Philomina J et al. J Infect. 2021 Aug.
No abstract available

Keywords: Breakthrough infection; COVID-19; SARS-CoV-2; Vaccine; Whole-genome sequencing.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors report no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
(A) History and timelines of infection for the 6 patients and intervals between the second dose of vaccine and date of RT-PCR testing (B) Presence of variants in the genome isolates of the 6 cases (P1–P6). (C) Phylogenetic context of the 6 genome isolates with 2630 additional SARS-CoV-2 genomes from the state of Kerala.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Tré-Hardy M., Cupaiolo R., Papleux E. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. 2021 doi: 10.1016/j.jinf.2021.03.025. S0163-4453(21)00158-4. - DOI - PMC - PubMed
    1. Ella R., Vadrevu K.M., Jogdand H. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21:637–646. - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Breakthrough COVID19 Infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021 Available at: http://dx.doi.org/10.1016/j.dsx.2021.05.001. Accessed 9 May 2021. - PMC - PubMed
    1. Emary K.R.W., Golubchik T., Aley P.K. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362. - PMC - PubMed